To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

Completed · Phase 2

Conditions studied: Alzheimer Disease

In brief

This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.

Key facts

Study ID

NCT01023685

Run by

Novartis

People needed

24

Starts

2009-12-01

Expected to finish

2012-02-01

Last updated by the study team

2020-12-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have completed the core study with no significant safety concerns

You may not qualify if…

• Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression).
• Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease.
• Diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• ATP Clinical Research, Inc. — Costa Mesa, California, United States
• Alpin Research Center — Boulder, Colorado, United States
• Sunrise Clinical Research, Inc. — Hollywood, Florida, United States
• Alexian Brothers Neuroscience Institute — Elk Grove Village, Illinois, United States
• Indiana University School of Medicine — Indianapolis, Indiana, United States
• Drexel University College of Medicine — Philadelphia, Pennsylvania, United States
• Volunteer Research Group — Knoxville, Tennessee, United States
• University of Texas Southwestern — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.